Payment overview · 2025
General Payments
$681.82
30 reported records · 13 companies
Healthcare provider profile · identity verified
Rex Shad Morgan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MT PLEASANT, SC · NPI 1992771000
Verified facts
What the public records show
CMS Open Payments records show Rex Shad Morgan, MD received $681.82 in general payments during 2025 across 30 reported records.
Amgen Inc. accounted for 36.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $250.94 | 36.8% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $122.67 | 18.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $52.30 | 7.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.34 | 5.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $37.15 | 5.5% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $34.58 | 5.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.36 | 4.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $26.27 | 3.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.96 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.15 | 2.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.95 | 2.3% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $14.87 | 2.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.28 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $681.82 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $193.63 | 7 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $69.76 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.76 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $52.30 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $51.43 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $38.34 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $34.58 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $31.36 | 1 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $26.27 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $14.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 167 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
81 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
167 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 675 | 187 |
| Atorvastatin Calcium | Atorvastatin Calcium | 648 | 170 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 455 | 124 |
| Losartan Potassium | Losartan Potassium | 444 | 116 |
| Escitalopram Oxalate | Escitalopram Oxalate | 390 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 348 | 87 |
| Lisinopril | Lisinopril | 289 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 274 | 70 |
| Gabapentin | Gabapentin | 246 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 234 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 225 | 63 |
| Omeprazole | Omeprazole | 217 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 205 | 39 |
| Trazodone Hcl | Trazodone Hcl | 188 | 54 |
| Donepezil Hcl | Donepezil Hcl | 187 | 37 |
| Alprazolam | Alprazolam | 181 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 44 |
| Eliquis | Apixaban | 167 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 48 |
| Metformin Hcl Er | Metformin Hcl | 150 | 40 |
| Tramadol Hcl | Tramadol Hcl | 121 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 31 |
| Simvastatin | Simvastatin | 117 | 38 |
| Famotidine | Famotidine | 110 | 36 |
| Metformin Hcl | Metformin Hcl | 110 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 42 |
| Sertraline Hcl | Sertraline Hcl | 107 | 28 |
| Meloxicam | Meloxicam | 106 | 27 |
| Furosemide | Furosemide | 104 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 96 | 18 |
| Prednisone | Prednisone | 95 | 49 |
| Alendronate Sodium | Alendronate Sodium | 92 | 23 |
| Potassium Chloride | Potassium Chloride | 91 | 33 |
| Bupropion Xl | Bupropion Hcl | 90 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 21 |
| Ozempic | Semaglutide | 87 | 14 |
| Allopurinol | Allopurinol | 86 | 25 |
| Buspirone Hcl | Buspirone Hcl | 81 | 19 |
| Lorazepam | Lorazepam | 81 | 22 |
| Montelukast Sodium | Montelukast Sodium | 81 | 19 |
| Mounjaro | Tirzepatide | 81 | 11 |
| Ezetimibe | Ezetimibe | 80 | 22 |
| Clonazepam | Clonazepam | 79 | 14 |
| Memantine Hcl | Memantine Hcl | 78 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 74 | 24 |
| Mirtazapine | Mirtazapine | 73 | 18 |
| Carvedilol | Carvedilol | 69 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 65 | 17 |
| Celecoxib | Celecoxib | 64 | 16 |
| Pregabalin | Pregabalin | 64 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 14 |
| Finasteride | Finasteride | 62 | 16 |
| Naproxen | Naproxen | 59 | 30 |
| Atenolol | Atenolol | 57 | 19 |
| Diazepam | Diazepam | 54 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 12 |
| Glipizide | Glipizide | 49 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 48 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Spironolactone | Spironolactone | 48 | 13 |
| Synthroid | Levothyroxine Sodium | 47 | 13 |
| Valsartan | Valsartan | 47 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 11 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Methadone Hcl | Methadone Hcl | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Glipizide Er | Glipizide | 40 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 31 |
| Olanzapine | Olanzapine | 36 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 27 |
| Risperidone | Risperidone | 31 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 12 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 16 |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 18 |
| Mupirocin | Mupirocin | 20 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 12 |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $681.82 · 30 records | Amgen Inc. | AMS 700, Auvelity, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, Flexitouch Plus, GEMTESA, NUPLAZID, NURTEC ODT, Nimbl, PROLIA, REPATHA, REXULTI, Veozah | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error